Argus Upgrades GlaxoSmithKline (GSK) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novartis (NVS)/ GlaxoSmithKline (GSK) Deal Makes Strategic Sense, Says Analyst
April 22, 2014 9:12 AM EDTNovartis (NYSE: NVS) announced that it has reached a definitive agreement with GlaxoSmithKline plc (NYSE: GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Analyst Mark Clark of Deutsche Bank said the deal makes strategic sense for GlaxoSmithKline.
"In a complex, three-part inter-conditional deal, GSK will: (1) assume control of Novartis OTC business (in return for granting Novartis a 36.5% stake in the combined Consumer Health business); (2) divest its marketed... More
Novartis (NVS), Galxo (GSK) Enter Major Asset Exchange Agreement (LLY)
April 22, 2014 8:59 AM EDTNovartis (NYSE: NVS) announced that it has reached a definitive agreement with GlaxoSmithKline plc (NYSE: GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them. The two companies would also create a joint venture, combining their consumer divisions to create a world-leading consumer healthcare business. Separately, the company announced a definitive agreement with Eli Lilly and Company (NYSE:... More
